Genetic variants are implicated in the development of amyotrophic lateral sclerosis (ALS), but it is unclear whether the burden of rare variants in ALS genes has an effect on survival. We performed whole genome sequencing on 8 familial ALS (FALS) patients with superoxide dismutase 1 (SOD1) mutation and whole exome sequencing on 46 sporadic ALS (SALS) patients living in Hong Kong and found that 67% had at least one rare variant in the exons of 40 ALS genes; 22% had two or more. Patients with two or more rare variants had lower probability of survival than patients with zero or one variant (p= 0.001). After adjusting for other factors, each additional rare variant increased the risk of respiratory failure or death by 60% (p=0.0098). Presence of rare variant was associated with risk of ALS (OR 1.91, 95% CI 1.03-3.61, p=0.03), and ALS patients had higher rare variant burden than controls (MB, p=0.004). Our findings support an oligogenic basis with burden of rare variants affecting the development and survival of ALS.
Introduction
Amyotrophic lateral sclerosis (ALS) is characterized by degeneration of motor neurons, progressive paralysis and death. The world-wide incidence of ALS is 0.3 to 7.0 per 100,000 per year (Cronin et al, 2007) and in Hong Kong, the incidence of ALS was estimated to be 0.6 per 100,000 per year (Fong et al, 2005) . Five to 10% of cases are familial. There are more than 20 known causative genes, with more showing association with risk of disease (Leblond et al, 2014) . Mutations in superoxide dismutase 1 (SOD1) and chromosome 9 open reading frame 72 (C9ORF72), the two most common causes of familial ALS (FALS) in populations of European ancestry, account for about half of familial cases collectively (Finsterer and Burgunder, 2014) .
Mutations in ALS genes are also found in 10% of patients with sporadic ALS (SALS) (Renton et al, 2014) . While twin studies from European populations showed ALS heritability to be around 61% in sporadic cases (Al-Chalabi et al, 2010) , genome-wide association analyses showed that common single nucleotide polymorphisms (SNPs) contribute to 8.5%-12% of sporadic ALS heritability (Fogh et al, 2014 , van Rheenen et al, 2016 . The difference in these heritability estimates, or "missing heritability", suggests that there is a notable genetic role in ALS that remains to be elucidated.
There is considerable variability in ALS phenotype: age and site of onset, relative degree of upper and lower motor neuron involvement, and rate of progression (Swinnen and Robberecht, 2014) . We previously described a Chinese kindred of FALS with SOD1 mutation with considerable intrafamilial phenotypic variability (Fong et al, 2006; Ng et al, 2008) . Identification of patients with mutations in more than one gene has led to the hypothesis of an oligogenic model of ALS, with 4.0% of M A N U S C R I P T
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Pang 4 FALS and 1.3% of SALS patients carrying multiple variants in one study (Kenna et al, 2013 ). Patients harboring rare variants in more than 1 gene had disease onset ten years earlier than subjects with variants in a single gene (Cady et al, 2015) . We therefore hypothesized that there is an oligogenic influence on survival in familial and sporadic ALS. We characterized the presence and burden of rare variants in 40 ALS genes in 8 FALS and 46 SALS patients.
Patients and methods

Subjects
ALS patients diagnosed and followed up at Queen Mary Hospital (QMH), Hong
Kong since 1997 were enrolled. They all fulfilled the criteria for definite ALS, probable ALS or probable ALS -laboratory-supported based on the revised El Escorial criteria (Brooks et al, 2000) .
Familial ALS
Eight ALS patients from 4 Chinese families in Hong Kong were included. They have been previously confirmed to harbor c.449T>C:p.I150T SOD1 mutation. Five (F19, F21, F204, F310, F331) came from the same kindred (supplementary figure 1). FAIII-16, FBIII-9, and FC-I came from three different families in Hong Kong.
Sporadic ALS
Forty-six SALS patients were included. Information on sex, age and site of onset, treatment with riluzole, and survival as defined by time from symptom onset to ventilation (non-invasive or invasive) or time to death (non-ventilated subjects), whichever is earlier, were recorded. We measured survival in terms of time from symptom onset to ventilatory failure or death, whichever is earlier, to avoid M A N U S C R I P T
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Pang 5 confounding effect of ventilatory support on survival. Genetic relatedness was measured by pi-hat.
Controls
Six hundred and ninety-nine exomes from volunteer-based healthy controls in Hong Kong were used for case-control association tests. Whole exome sequencing was performed using Illumina TruSep Exome capture kits with 48X coverage overall followed by the same procedures as ALS subjects. Only protein coding regions were included for downstream analyses. Principal component analysis (PCA) was performed to check the population stratification between ALS and control (Yang et al, 2011; Chang et al, 2015) .
Patient consents
This study has been approved by the Hong Kong Hospital Authority/Hong Kong West Cluster Institutional Review Board Ethics Committee and all participants gave written informed consent to participate.
Genotyping and rare variants filtering
Whole genome sequencing (WGS) was performed on 8 FALS patients. Whole exome sequencing (WES) was performed on 46 SALS patients using Nimblegen SeqCap EZ Human Exome Kit v3.0 capture kits. Illumina Hiseq 2000 system with 100bp pair-end reads was used on both WGS and WES. The sequencing coverage reached at least 33X and 95X respectively. GATK (The Genome Analysis Toolkit) best practices pipeline was adopted for sequencing data processing and variant calling analysis (McKenna et al, 2010) . Another independent sample in the same sequencing batch consisting of 28 controls from the same population, using the same capture kits and M A N U S C R I P T
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Pang 6 sequencing machine, was used to filter out any potential batch effect and system bias.
Variant annotation and filtering were performed by KGGSeq (Li et al, 2012; Hsu et al, 2016) . As ALS is a rare disease, only non-synonymous variants with minor allele frequency (MAF) of less than 0.1% across all populations in Exome Aggregation Consortium (ExAC) dataset were selected (http://exac.broadinstitute.org). All of the variants had a sequencing quality score (Phred) of at least 50 and mapping quality score of at least 20. Only those alternative alleles with more than 25% of total reads were considered as heterozygous alleles. Phred-scaled p-value using Fisher's exact test (FS) was less than 60, which excluded strand bias.
ALS Candidate Genes
Forty protein-coding genes: 14 causative ALS genes, 24 susceptibility risk genes (Leblond et al, 2014) , and 2 recently described genes from a large-scale ALS exome study (Cirulli et al, 2015) were examined for novel and rare variants (Supplementary Table 1 ).
Survival analysis
The Kaplan-Meier survival analysis was used to measure the effect of rare variant burden on the time to ventilator or death. We defined patients started on non-invasive ventilatory support (NIV) as reaching the endpoint of ventilatory failure since in our center NIV support was only initiated in patients with respiratory failure. All but 1 patient who received NIV had expressed their wish against intubation, and none of them would have survived much longer without NIV support. After adjusting for onset age, censorship, sex, onset region, inheritance (familial or sporadic) and riluzole treatment, Cox regression was performed to estimate the proportional hazard ratio of rare variant burden on survival.
Rare variant association test
Rare variant association tests between case and control were performed by RVTESTS (Zhan et al, 2016) and KGGSeq integrated SKAT package (Ionita-Laza et al, 2013) on 3 levels: single variant, gene, and gene set. Collapsing and combining rare variants followed by Fisher's exact test (CMCFisher), up-weighing rare variant using inverse frequency from controls (Madsen-Browning) and Sequencing Kernel Association Test (SKAT and SKATO) were selected to evaluate rare variant burden association.
Results
Familial ALS
The mean (SD) age of onset of the 8 FALS patients (3 males, 5 females) was 41.4 Survival time was largely variable in the 8 familial patients among the 4 kindreds we have analyzed. From the same kindred, F19 had the shortest survival of 3 months, followed by F21 and F204 (11 months). F310 and F331 had longer survival of 37 (and still alive) and 74 months respectively. FA-III-16, FB-III-9, and FC-I, from 3 different families, had longer survival of 76, 50 and 80 months respectively.
In the exons of 40 ALS genes, F19 had 2 additional rare variants: ALS2 p.L520F and DAO p.P103L (table 2; supplementary table 2) . F21 had 1 additional rare variant in
0.00009). We excluded this variant from the downstream survival and case-control association analyses because only 74.9% of the control subjects had adequate coverage for this locus (vs. 100 % of cases). FB-III-9 had 3 additional rare variants (NEK1 p.P287A, SETX p.M2324I, and an additional SOD1 variant p.D93G). In contrast, F331 and FA-III-16 who survived for more than 70 months, and the 2 surviving subjects (F310, FC-I), had no additional rare variant. Overall, FALS patients with 2 or more rare variants appear to have shorter time to ventilator dependence or death.
Sporadic ALS
The mean (SD) age of onset in SALS was 58.1(±13.45) years including censored patients, and 60.9% of the patients were male (table 1). Twenty patients (43.5%) had bulbar onset. Two patients received riluzole for at least one month. Forty patients had reached the endpoint after a median of 34 (Interquantile range[IQR] 13-42) months.
Twenty-eight patients (60.8%) had at least 1 rare variant within the 40 ALS genes, and 9 (19.5%) had 2 or more rare variants (supplementary table 3).
Novel and rare variant identification
Of the 40 genes examined, novel or rare variants (MAF ≤ 0.001) were found in 21 genes. Thirty-nine missense variants, occurring in 52 alleles, were identified. Nine novel variants that have not been described in the ExAC (table 2) occurred in 10 SALS patients. Five patients with a novel variant (VCP p.G157R, TARDBP p.G298S, TARDBP p.M337V or ARHGEF2 p.G1029W) had no additional variants, suggesting a possible causal effect of these variants in ALS. Excluding the SOD1 mutation, 5 (13.2%) and 3 (7.9%) of the remaining 38 rare variants have been previously reported
in ALSdb (http://alsdb.org/) and ALSoD (http://alsod.iop.kcl.ac.uk/) (Abel et al, 2012 ) databases respectively. No variants were found to be significantly associated with survival probability at the variant or gene level.
The most frequently found variant occurred in NEK1 (p.P287A) in 1 FALS and 2 SALS patients (1 with short survival, 2 with long survival). A rare variant in DAO (p.P103L) was found in 2 FALS patients (F19 and F21), both with a survival <12 months. Two rare variants were found in ITPR2 in 2 SALS patients (p.M2443T, p.V1952A), both with a survival <18 months. A novel variant in TARDBP (p.G298S) was shared by 2 SALS patients (MND19 and MND40), both survived <18 months.
Another patient (MND4) with long survival (164 months) had a different rare variant in TARDBP (p.M337V). Patients sharing the same rare variants had pi-hat values ranging from 0 to 0.022, indicating that they are likely to be genetically independent (Supplementary table 4) .
Effect of variant burden on survival
FALS patients with survival of less than a year all had additional rare variants. The patient (F19) with the shortest survival had the highest number of rare variants. These observations suggested that burden of rare variants may have an effect on survival, with each additional variant reducing survival probability. Combining FALS and SALS patients, we found that higher variant burden is associated with lower survival probability (Log Rank test X 2 (2, N=54)= 13.2, p= 0.00137, figure 1). Patients with 2 or more rare variants had reduced survival probability compared with patients with 0 or 1 variant (Log Rank test X 2 (1, N=54)= 13.1, p=0.00029). At 15 months after symptom onset, only 33% (4/12) patients with 2 or more variants were alive without M A N U S C R I P T 
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Effect of rare variants on risk of developing ALS
Next we examined if presence of rare variants in our gene set contributes also to risk of developing ALS. Principal Component Analysis (PCA) for common variants (MAF > 5%) confirmed that ALS patients and healthy controls had similar genetic background (Supplementary figure 2). Thirty-five of 54 patients (65%) had at least 1 non-synonymous rare variant among the 40 selected ALS genes, with an average rare variant burden of 0.96, which is higher than the 0.68 in controls (odds ratio 1.91, 95% CI 1.03-3.61, see mutations are more common in Asians (Soong et al, 2014; Kim et al, 2016; Nakamura et al, 2016) . For this study we have included genes that are commonly mutated in Asian ALS patients.
In our 8 FALS patients sharing the same SOD1 mutation, there was wide variability in survival. Therefore, we looked for additional genetic variants which may explain this M A N U S C R I P T
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Pang 12 variability. We observed that FALS patients with additional rare variants had shorter survival. Combining FALS and SALS patients, we confirmed that patients with two or more variants had shorter survival, suggesting an accumulative effect of rare genetic variants on reducing survival probability. This was confirmed by gene set analysis, which showed that variant burden within these 40 ALS genes was associated with survival probability.
We included FALS patients in the gene set association analyses (table 3) 
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We also showed in this study that ALS patients more often had rare variants within the 40 ALS genes than healthy controls. This suggests that deleterious variants across a set of biologically relevant genes may be responsible for the development of ALS.
Our findings are in accordance with another study which showed that there was a significant enrichment of deleterious rare or novel alleles in ALS patients compared with controls, and that 60% of SALS patients had rare or novel variants in 169 ALS genes (Couthouis et al, 2014) . With fewer candidate genes, we showed that 60.8% of SALS had at least 1 and 19.5% had 2 or more rare variants. This observation confirmed the importance of these 40 ALS risk genes in disease etiology.
In a large scale WES study, DAO was found to correlate with survival time (Cirulli et al, 2015) . In our study, rare variants in DAO were identified in 2 FALS patients and 1 SALS patient, all with short survival of less than 1 year. Similarly, we found 2 rare variants in ITPR2 in 2 SALS patients, both with short survival. Our findings suggest that DAO and ITPR2 may be important in modifying disease course and deserve further studies. We also confirmed the importance of NEK1 and TBK1, two recently implicated ALS genes, as variants in both genes have been identified in our ALS showed that 27.8% of SALS patients had one or more rare variants (Cady et al, 2015) .
Looking at the exons of these 17 genes in our patients, we saw a comparable proportion (30.4%) with 1 or more rare variant. The previous study showed no association between rare variant burden and disease duration. In contrast, using our list of 40 genes, with a smaller sample size, we showed that rare variant burden was associated with reduced survival. This is likely because our expanded gene list conferred more power to detect associations between clinical features and rare variant burden.
Genome-wide association studies (GWASs) have estimated that common genetic variants account for 8.5%-12% of heritability of ALS (Fogh et al, 2014; van Rheenen et al, 2016) . Using genome-wide complex trait analysis looking at common variants in ALS patients, another study further increased the heritability estimate to 21% (Keller et al, 2014) , while twin studies showed ALS heritability to be around 61%
(Al-Chalabi, 2010). The "missing heritability" is likely due to rare variants, and our study confirmed that a notable proportion of sporadic ALS patients carried rare variants in ALS risk and susceptibility genes.
Just as we have shown that rare variants can influence survival in ALS, common variants may also play a role. A genome-wide association study carried out in patients from Europe and the United States identified common variants in CAMTA1 to be associated with survival (Fogh et al, 2016) . In our 54 patients, 5 carried rare nonsynonymous variant in CAMTA1: F21, F310, and MND64 carried the same rare variant (p.V949L) and had survival of 11, 37 and 3 months respectively. F331 carried M A N U S C R I P T There are some limitations to our study. Our sample size is small. However, because all patients were seen in a single center, we have detailed phenotype information enabling analysis for genotype-phenotype correlation. We only examined the exons of 40 genes for non-synonymous missense mutations. Repeat expansions, variants located in non-coding regions, and copy number variations would not be detected in our study. We did not screen for the hexanucleotide repeat expansion in C9ORF72, the most common genetic cause of ALS in the west, but this mutation is exceedingly rare in Chinese, Koreans and Japanese (Kim et al, 2016; Nakamura et al, 2016; He et al, 2016) . Similarly, repeat expansions in ATXN2 and copy number variations in SMN1 were not included in our study. Although it is not known if non-synonymous single nucleotide variants (SNVs) in C9ORF72 and ATXN2 cause ALS, we nevertheless included these genes in our analysis to look for presence of variants in the exons of these genes in ALS patients. In fact, a recent study which included 469
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Japanese ALS patients identified an SNV in C9ORF72 in one patient, while no repeat expansion was detected (Nakamura et al, 2016 ). There are various models which provide pathogenicity predictions of variants (Supplementary table 5 The differences were evaluated by the Log-rank test with two degrees of freedom.
RV=rare variant. N= number of patients.
